EUVIMEDEUVIMED entdecken
Open Access

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Chuan Angel Lu, Changchuan Jiang, Andrew Z Wang, Tian Zhang

JAMA Network Open · 29.05.2026 · 9 (5) · e2612707

DOI: 10.1001/jamanetworkopen.2026.12707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 29.05.2026. Verfasst von Chuan Angel Lu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical C…. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Immune Checkpoint Inhibitors, Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition enhances antitumor efficacy of immune checkpoint inhibitors (ICIs) in preclinical models, but clinical evidence remains limited.

Objective

To compare survival and selected clinical outcomes among adults receiving ICIs for cancer who were treated with a PCSK9 inhibitor (PCSK9I) compared with high-intensity statin therapy. Design, Setting, and Participants This comparative effectiveness study used deidentified data from the TriNetX research network. Adults with non–small cell lung cancer, melanoma, or renal cell carcinoma who received a programmed cell death 1 or a programmed cell death ligand 1 inhibitor between January 1, 2016, and December 31, 2024, were included. Follow-up began from ICI treatment initiation through January 13, 2026. Exposure Patients with PCSK9I exposure within 1 year before ICI treatment initiation were compared with those receiving high-intensity statins without PCSK9I use. One-to-one propensity score matching was performed, followed by Kaplan-Meier and Cox proportional hazards regression analyses. Main Outcomes and Measures Primary outcomes were overall survival and a modified 4-point major adverse cardiovascular event (MACE) composite. Secondary outcomes included use of acute health care services (emergency department visits, hospitalization, and critical care services).

Results

Among 239 matched pairs of patients (478 patients; 273 [57.1%] male; mean [SD] age, 70.8 [8.5] years), the mean (SD) age was 70.7 (8.2) years in the PCSK9I cohort and 70.8 (8.7) years in the statin cohort; lung cancer was the most common malignant neoplasm (159 [66.5%] vs 150 [62.8%], respectively). During follow-up as long as 9 years, 99 deaths occurred in the PCSK9I cohort and 129 in the statin-only cohort. PCSK9I use was associated with improved survival (hazard ratio [HR], 0.69; 95% CI, 0.53-0.90; log-rank P = .006), with 2-year survival probabilities of 62% vs 51%. MACE did not differ significantly (73 vs 81 events; HR, 0.85; 95% CI, 0.62-1.16; P = .31). PCSK9I use was also associated with lower risks of emergency department visits (HR, 0.65; 95% CI, 0.49-0.86; P = .002), hospitalization (HR, 0.73; 95% CI, 0.57-0.92; P = .008), and use of critical care services (HR, 0.68; 95% CI, 0.48-0.96; P = .03). Conclusions and Relevance Among adults with non–small cell lung cancer, melanoma, or renal cell carcinoma receiving ICIs, PCSK9I use was associated with improved survival and reduced levels of acute health care utilization without significant differences in cardiovascular events, warranting further prospective investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsImmune Checkpoint InhibitorsNeoplasmsHydroxymethylglutaryl-CoA Reductase InhibitorsHumansMaleFemaleAgedMiddle AgedLung NeoplasmsCarcinoma, Non-Small-Cell LungKidney NeoplasmsCarcinoma, Renal CellMelanomaProprotein Convertase 9

Substanzen

PCSK9 InhibitorsImmune Checkpoint InhibitorsPCSK9 protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.
  • Peter O'Donnell Jr School of Public Health, University of Texas Southwestern Medical Center, Dallas.
  • Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas.

Zitieren

APA

Lu, C. A., Jiang, C., Wang, A. Z., & Zhang, T. (2026). Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer. JAMA Network Open, 9(5), e2612707. https://doi.org/10.1001/jamanetworkopen.2026.12707

Vancouver

Lu CA, Jiang C, Wang AZ, Zhang T. Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer. JAMA Network Open. 2026;9(5):e2612707. doi:10.1001/jamanetworkopen.2026.12707

BibTeX
@article{Lu2026,
  author = {Lu, Chuan Angel and Jiang, Changchuan and Wang, Andrew Z and Zhang, Tian},
  title = {Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {5},
  pages = {e2612707},
  doi = {10.1001/jamanetworkopen.2026.12707}
}
Kostenlos starten →